Target intelligence / Profile preview

Human leukocyte antigen B*57:01 (HLA-B*57:01) receptor (HLA-B*57:01)

Target
HLA-B*57:01
Molecular classification
Major histocompatibility complex (MHC) class I, Receptor
01

Overview

Human leukocyte antigen B*57:01 (HLA-B*57:01) is a specific allele of the HLA-B gene that encodes a Major Histocompatibility Complex (MHC) class I receptor (UniProt P01889). Its primary biological function is to present endogenous peptides to CD8+ cytotoxic T cells, which is essential for immune surveillance against viral infections and tumors (Illing et al., 2012). This molecule is a critical pharmacogenetic target because it mediates severe, potentially fatal hypersensitivity reactions to certain drugs, most notably the antiretroviral abacavir. Abacavir binds non-covalently within the F-pocket of the HLA-B*57:01 peptide-binding groove, altering the chemical environment and causing the receptor to present a different set of self-peptides (Ostrov et al., 2012). This altered peptide repertoire is recognized as foreign by the immune system, triggering a massive polyclonal T-cell activation known as Abacavir Hypersensitivity Syndrome (Mallal et al., 2008). Additionally, HLA-B*57:01 is associated with idiosyncratic drug-induced liver injury from agents such as flucloxacillin and pazopanib (Daly et al., 2009).

Other names
HLA-B*5701MHC class I antigen B*5701HLA-B*57:01-peptide complexMajor histocompatibility complex, class I, B*57:01
02

Mechanism of action

Drugs like abacavir bind non-covalently to the F-pocket of the HLA-B*57:01 peptide-binding groove, altering the chemical environment and the repertoire of self-peptides presented to CD8+ T cells, which triggers a systemic hypersensitivity response.

03

Biological functions

Antigen presentationImmune responseCD8+ T cell activation
04

Disease associations

Abacavir hypersensitivity syndromeDrug-induced liver injuryHIV-1 infectionPsoriasis
05

Safety considerations

Abacavir hypersensitivity syndrome (AHS)Drug-induced liver injury (DILI)Systemic inflammatory responseMulti-organ failure
06

Interacting drugs

Abacavir

2 more in the full profile.

07

Biomarkers

HLA-B*57:01 allele

Beyond the preview

Go deeper on Human leukocyte antigen B*57:01 (HLA-B*57:01) receptor (HLA-B*57:01).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human leukocyte antigen B*57:01 (HLA-B*57:01) receptor (HLA-B*57:01).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call